Post by icemandios on Aug 1, 2023 13:14:15 GMT
Pfizer Reports Second-Quarter 2023 Results
Second-Quarter 2023 Revenues from Comirnaty(1) and Paxlovid of $1.6 Billion
Continues to Make Significant Progress on Executing an Unprecedented Number of Product and Indication Launches Expected to Contribute to Non-COVID Operational Revenue Growth in the Second Half of 2023
Second-Quarter 2023 Revenues of $12.7 Billion
Expected Decline in Paxlovid and Comirnaty(1) Revenues Drove 53% Operational Decrease in Second-Quarter 2023 Revenues
Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 5% Operationally
Second-Quarter 2023 Reported Diluted EPS(2) of $0.41, a Year-Over-Year Decline of 77%, and Adjusted Diluted EPS(3) of $0.67, a Year-Over-Year Decline of 67%
Narrows 2023 Revenue Guidance(4) Range to $67 to $70 Billion and Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6% to 8%
Maintains All Other Components of Full-Year 2023 Financial Guidance(4), Including Guidance for Adjusted Diluted EPS(3)
Ngenla (somatrogon-ghla) – In June 2023, Pfizer and OPKO Health Inc. announced the FDA approved Ngenla, a once-weekly, human growth hormone analog for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Ngenla is approved for the treatment of pediatric growth hormone deficiency in more than 40 markets including Canada, Australia, Japan, and EU Member States.